Vectorite Biomedical Inc. (TPEX:4170)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
13.45
-0.65 (-4.61%)
At close: Mar 9, 2026
-3.93%
Market Cap 588.72M
Revenue (ttm) 67.90M
Net Income (ttm) -23.19M
Shares Out 43.77M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 74,615
Average Volume 47,677
Open 14.00
Previous Close 14.10
Day's Range 13.15 - 14.10
52-Week Range 10.40 - 18.15
Beta 0.35
RSI 40.88
Earnings Date Apr 27, 2026

About Vectorite Biomedical

Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company’s products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc. was incorporated in 2004 and is based in New Taipei City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4170
Full Company Profile

Financial Performance

In 2024, Vectorite Biomedical's revenue was 57.77 million, an increase of 3.43% compared to the previous year's 55.85 million. Losses were -40.05 million, 506.8% more than in 2023.

Financial Statements

News

There is no news available yet.